N-acetylcysteine as a novel prophylactic treatment for ifosfamide-induced nephrotoxicity in children: Translational pharmacokinetics

Journal of Clinical Pharmacology

Volumn 52, Issue 1, 2012, Pages 55-64

  Hanly, Lauren N ^a,b   Chen, Nancy ^a,b   Aleksa, Katarina ^c,d   Cutler, Murray ^a,e   Bajcetic, Milica ^f,g   Palassery, Rasmi ^h   Regueira, Osvaldo ^h   Turner, Curtis ^h   Baw, Bandar ⁱ   Malkin, Becky ^j   Freeman, David ^a,e   Rieder, Michael J ^a,j,k   Vasylyeva, Tetyana L ^h   Koren, Gideon ^a,b,c,l  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b WESTERN UNIVERSITY   (Canada)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d UNIVERSITY OF WATERLOO   (Canada)

^e LAWSON HEALTH RESEARCH INSTITUTE   (Canada)

^f UNIVERSITY CHILDREN S HOSPITAL   (Serbia)

^g UNIVERSITY OF BELGRADE   (Serbia)

^h TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

ⁱ MCMASTER UNIVERSITY   (Canada)

^j LONDON HEALTH SCIENCES CENTRE   (Canada)

^k CHILDREN S HOSPITAL OF WESTERN ONTARIO   (Canada)

^l UNIVERSITY OF TORONTO   (Canada)

more..

Author keywords

children; Ifosfamide; N acetylcysteine; nephrotoxicity; prevention

Indexed keywords

ACETYLCYSTEINE; ALPHA FETOPROTEIN; BLEOMYCIN; CARBOPLATIN; CHORIONIC GONADOTROPIN BETA SUBUNIT; CISPLATIN; CREATININE; DACTINOMYCIN; ETOPOSIDE; FUROSEMIDE; IFOSFAMIDE; MEROPENEM; MESNA; MORPHINE; ONDANSETRON; PACLITAXEL; PARACETAMOL; VINCRISTINE;

ACETAMINOPHEN OVERDOSE; ACUTE KIDNEY FAILURE; ADOLESCENT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN DISEASE; CANCER CHEMOTHERAPY; CANCER RELAPSE; CANCER SURGERY; CHILD; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CREATININE BLOOD LEVEL; DIALYSIS; DIURESIS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG OVERDOSE; ELECTROENCEPHALOGRAM; FASCICULATION; FEMALE; HUMAN; MALE; NEPHROTOXICITY; NEUROECTODERM TUMOR; NONHUMAN; ORCHIECTOMY; RAT; RENAL PROTECTION; SCHOOL CHILD; TESTIS TUMOR; URINE VOLUME; VOMITING;

ACETAMINOPHEN; ACETYLCYSTEINE; ACUTE KIDNEY INJURY; ADOLESCENT; ANALGESICS, NON-NARCOTIC; ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; AREA UNDER CURVE; CHILD; FEMALE; HUMANS; IFOSFAMIDE; MALE; OVERDOSE; PROTECTIVE AGENTS; RATS; RATS, WISTAR;

EID: 84855427456     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270010391790     Document Type: Article

References (54)

1. Dechant KL, Brodgden RN, Pilkington T, Faulds D. Ifosfamide/mesna: a review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer. Drugs. 1991 ; 42: 428-467 (Pubitemid 21920771)
2. de Kraker J. Ifosfamide in pediatric oncology. Anticancer Drugs. 1991 ; 2: 339-341
3. Brock N, Pohl J, Stekar J. Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention, I: experimental studies on the urotoxicity of alkylating compounds. Eur J Cancer. 1981 ; 16: 595-607 (Pubitemid 11047936)
4. Skinner R, Sharkey IM, Pearson ADJ, Craft AW. Ifosfamide, mesna, and nephrotoxicity in children. J Clin Oncol. 1993 ; 11: 173-190 (Pubitemid 23059992)
5. Jurgens H, Treuner H, Winkler K, Gobel U. Ifosfamide in pediatric malignancies. Semin Oncol. 1989 ; 16: 46-50 (Pubitemid 19116956)
6. Cohen MH, Dagher R, Griebel DJ, et al. U.S. Food and Drug Administration drug approval summaries: imatinib mesylate, mesna tablets, and zoledronic acid. Oncologist. 2002 ; 7: 393-400
7. Loebstein R, Koren G. Ifosfamide-induced nephrotoxicity in children: critical review of predictive risk factors. Pediatrics. 1998 ; 101: E8 - E12
8. Rosoff PM. The two-edged sword of curing childhood cancer. N Engl J Med. 2006 ; 355: 1522-1523 (Pubitemid 44547804)
9. Chang TKH, Weber GF, Crespi CL, Waxman DJ. Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in microsomes. Cancer Res. 1993 ; 53: 5629-5637 (Pubitemid 23360263)
10. Walker D, Flinois JP, Monkman SC, et al. Identification of the major human hepatic cytochrome P450 involved in activation and N-decholorethylation of ifosfamide. Biochem Pharmacol. 1994 ; 47: 1157-1163
11. Huang Z, Roy P, Waxman DJ. Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide. Biochem Pharmacol. 2000 ; 59: 961-972 (Pubitemid 30110812)
12. Springate JE, Van Liew JB. Nephrotoxicity of ifosfamide in rats [letter]. J Appl Toxicol. 1995 ; 15: 399-402
13. Springate JE, Chan K, Lu H, Davies S, Taub M. Toxicity of ifosfamide and its metabolite chloroacetaldehyde in cultured renal tubule cells. In Vitro Cell Dev Biol Anim. 1999 ; 35: 314-317 (Pubitemid 29288354)
14. Dubourg L, Michoudet C, Cochat P, Baverel G. Human kidney tubules detoxify chloroactetaldehyde, a presumed nephrotoxic metabolite of ifosfamide. J Am Soc Nephrol. 2001 ; 12: 1615-1623 (Pubitemid 32674423)
15. Woodland C, Ito S, Granvil CP, Wainer IW, Klein J, Koren G. Evidence of renal metabolism of ifosfamide to nephrotoxic metabolites. Life Sci. 2000 ; 68: 109-117
16. Chen N, Aleksa K, Woodland C, Rieder MJ, Koren G. N-acetylcysteine prevents ifosfamide-induced nephrotoxicity in rats. Br J Pharmacol. 2008 ; 153: 1364-1372 (Pubitemid 351481517)
17. Chen N, Aleksa K, Woodland C, Rieder MJ, Koren G. The effect of N-acetylcysteine on ifosfamide-induced nephrotoxicity: in vitro studies in renal tubular cells. Transl Res. 2007 ; 150: 51-57 (Pubitemid 46935594)
18. Benesic A, Schwerdt G, Mildenberger S, Freudinger R, Gordjani N, Gekle M. Disturbed Ca2+-signaling by chloroacetaldehyde: a possible cause for chronic ifosfamide nephrotoxicity. Kidney Int. 2005 ; 68: 2029-2041 (Pubitemid 43117778)
19. Sehirli O, Sakarcan A, Velio lu-O ünç A, et al. Resveratrol improves ifosfamide-induced Fanconi syndrome in rats. Toxicol Appl Pharmacol. 2007 ; 222: 33-41 (Pubitemid 46962655)
20. Sener G, Sehirli O, Yegen BC, Cetinel S, Gedik N, Sakarcan A. Melatonin attenuates ifosfamide-induced Fanconi syndrome in rats. J Pineal Res. 2004 ; 37: 17-25 (Pubitemid 38976501)
21. De Vries N, De Flora S. N-acetyl-l-cysteine. J Cell Biochem. 1993 ; 17F: S270 - S277
22. Kelly GS. Clinical applications of N-acetylcysteine. Altern Med Rev. 1998 ; 3: 114-127 (Pubitemid 128709607)
23. De Flora S, Bennicelli C, Camoirano A, et al. In vivo effects of N-acetylcysteine on glutathione metabolism and on the biotransformation of carcinogenic and/or mutagenic compounds. Carcinogenesis. 1985 ; 6: 1735-1745 (Pubitemid 16168985)
24. Prescott LF, Illingworth RN, Critchley JA, Stewart MJ, Adam RD, Proudfoot AT. Intravenous N-acetylcystine: the treatment of choice for paracetamol poisoning. Br Med J. 1979 ; 2: 1097-1100 (Pubitemid 10249121)
25. Prescott LF, Park J, Ballantyne A, Adriaenssens P, Proudfoot AT. Treatment of paracetamol (acetaminophen) poisoning with N-acetylcysteine. Lancet. 1977 ; 2: 432-434 (Pubitemid 8167941)
26. Sehirli AO, Sener G, Satiroglu H, Ayanoglu-Dulger G. Protective effect of N-acetylcysteine on renal ischemia/reperfusion injury in the rat. J Nephrol. 2003 ; 16: 75-80
27. Mishima K, Baba A, Matsuo M, Itoh Y, Oishi R. Protective effect of cyclic AMP against cisplatin-induced nephrotoxicity. Free Radic Biol Med. 2006 ; 40: 1564-1577
28. Tariq M, Morais C, Sobki S, Al Sulaiman M, Al Khader A. N-acetylcysteine attenuates cyclosporin-induced nephrotoxicity in rats. Nephrol Dial Transplant. 1999 ; 14: 923-929 (Pubitemid 29155148)
29. Badary O. Taurine attenuates Fanconi syndrome induced by ifosfamide without compromising its antitumor activity. Oncol Res. 1998 ; 10: 355-360 (Pubitemid 128736333)
30. Nissim I, Weinberg JM. Glycine attenuates Fanconi syndrome induced by maleate or ifosfamide in rats. Kidney Int. 1996 ; 49: 684-689
31. Bardary O. L-histidinol attenuates Fanconi syndrome induced by ifosfamide in rats. Exp Nephrol. 1999 ; 7: 323-327
32. Badary O. Thymoquinone attenuates ifosfamide-induced Fanconi syndrome in rats and enhances its antitumor activity in mice. J Ethnopharmacol. 1999 ; 67: 135-142 (Pubitemid 29421667)
33. Ivanenko A, Crabtree VM, Tauman R, Gozal D. Melatonin in children and adolescents with insomnia: a retrospective study. Clin Pediatr. 2003 ; 42: 51-58 (Pubitemid 36159333)
34. Andersen IM, Kaczmarska J, McGrew SG, Malow BA. Melatonin for insomnia in children with autism spectrum disorders. J Child Neurol. 2008 ; 5: 482-485 (Pubitemid 351566859)
35. van der Spuy WJ, Pretorius E. Is the use of resveratrol in the treatment and prevention of obesity premature?. Nutr Res Rev. 2009 ; 2: 111-117
36. Tsai CL, Chang WT, Weng TI, Fang CC, Walson PD. A patient-tailored N-acetylcysteine protocol for acute acetaminophen intoxication. Clin Ther. 2005 ; 27: 336-341 (Pubitemid 40692752)
37. Nishida T, Matsura T, Nakada J, et al. Geranylgeranylacetone protects against acetaminophen-induced hepatotoxicity by inducing heat shock protein 70. Toxicology. 2006 ; 219: 187-196 (Pubitemid 43120719)
38. Woodcock J. A difficult balance: pain management, drug safety, and the FDA. N Engl J Med. 2009 ; 36: 22
39. Prescott LF, Illingworth RN, Critchley JA, Stewart MJ, Adam RD, Proudfoot AT. Intravenous N-acetylcysteine: the treatment of choice for paracetamol poisoning. Br Med J. 1979 ; 2 (6198). 1097-1100 (Pubitemid 10249121)
40. Rowden AK, Norvell J, Eldridge DL, Kirk MA. Updates on acetaminophen toxicity. Med Clin North Am. 2005 ; 89: 1145-1159 (Pubitemid 41446566)
41. Nashville, Tenn: Cumberland Pharmaceuticals ; 2004 :
42. Borgstrom L, Kagedal B, Paulsen O. Pharmacokinetics of N-acetylcysteine in man. Eur J Clin Pharmacol. 1896 ; 31: 217-222
43. Woo O, Mueller PD, Olson KR, Anderson IB, Kim SY. Shorter duration of oral N-acetylcysteine therapy for acute acetaminophen overdose. Ann Emerg Med. 2000 ; 35: 363-368 (Pubitemid 30643555)
44. Smilkstein M, Bronstein AC, Linden C, Augenstein WL, Kulig KW, Rumack BH. Acetaminophen overdose: a 48-hour intravenous N-acetylcysteine treatment protocol. Ann Emerg Med. 1991 ; 10: 1058-1063
45. Algren A. Review of N-acetylcysteine for the treatment of acetaminophen (paracetamol) toxicity in paediatrics. Paper presented at: Second Meeting of the Subcommittee of the Expert Committee on the Selection and Use of Essential Medicines Geneva ; ;..
46. Mullins ME, Schmidt RU, Jang TB. What is the rate of adverse events with intravenous versus oral N-acetlycysteine in pediatric patients?. Ann Emerg Med. 2004 ; 44: 547-548
47. Whyte IM, Francis B, Dawson AH. Safety and efficacy of intravenous N-acetylcysteine for acetaminophen overdose: analysis of the Hunter Area Toxicology Service (HATS) database. Curr Med Res Opin. 2007 ; 23: 2359-2368 (Pubitemid 350033437)
48. Buckley NA, Whyte IM, O'Connell DL, Dawson AH. Oral or intravenous N-acetylcysteine: which is the treatment of choice for acetaminophen (paracetamol) poisoning?. Clin Toxicol. 1999 ; 37: 759-767
49. Mant TK, Tempowski JH, Volans GN, Talbot JC. Adverse reactions to acetylcysteine and effects of overdose. Br Med J. 1984 ; 289: 217-219 (Pubitemid 14014338)
50. Lynch RM, Robertson R. Anaphylactoid reactions to intravenous N-acetylcysteine: a prospective case controlled study. Accid Emerg Nurs. 2004 ; 12: 10-15 (Pubitemid 38041234)
51. Zyoud SH, Awang R, Syed Sulaiman SA, Sweileh WM, Al-Jabi SW. Incidence of adverse drug reactions induced by N-acetylcysteine in patients with acetaminophen overdose. Hum Exp Toxicol. 2010 ; 29: 153-160
52. Mroz LS, Benitez JG, Krenzelok EP. Angioedema with oral N-acetylcysteine. Ann Emerg Med. 1997 ; 30: 240-241
53. Jacobsen DW, Gatautis VJ, Green R, et al. Rapid HPLC determination of total homocysteine and other thiols in serum and plasma: sex differences and correlation with cobalamin and folate concentrations in healthy subjects. Clin Chem. 1994 ; 40: 873-881 (Pubitemid 24166304)
54. Aleksa K, Nava-Ocampo A, Koren G. Detection and quantification of (R) and (S)-dechloroethylifosfamide metabolites in plasma from children by enantioselective LC/MS/MS. Chirality. 2009 ; 21: 674-680